Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer-who benefits?

Strahlenther Onkol · 2022 · PMC9700570 · PMID 35416495

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

almost significantp = 0.061so close (0.05 < p ≤ 0.1)

In subgroup analyses for comorbidities regarding differences in OS, the superiority of the nRCT‐S remained almost significant for CCI values 2–6 ( p = 0.061).

also in 1,858 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.